Abstract: The disclosure relates to a chewable medicated composition comprising sennosides as the active ingredient and at least one excipient, wherein the bitter taste of sennosides is masked and the composition is substantially free of sugar.
Abstract: Embodiments of the present application relate to N-acetylgalactosamine-conjugated nucleosides. In particular, the N-acetylgalactosamine is installed on the nucleobase of the nucleosides through a wide variety of linkers. Methods of making N-acetylgalactosamine-conjugated nucleosides are also disclosed herein. N-acetylgalactosamine is a well-defined liver-targeted moiety and N-acetylgalactosamine-conjugated nucleosides may be used in the preparation of targeted delivery of oligonucleotide-based therapeutics.
Type:
Grant
Filed:
June 16, 2022
Date of Patent:
May 16, 2023
Assignee:
Hongene Biotech Corporation
Inventors:
Xiaoyang Guan, David Yu, Ruiming Zou, Xiaoling Zheng, John Liu, Aldrich N. K. Lau, Wing C. Poon, Gang Zhao, Gengyu Du, Yun-Chiao Yao
Abstract: Present invention relates to a process to reduce butane sultone hydrolysis products (4-hydroxybutane-1-sulfonic acid, and bis(4-sulfobutyl) ether disodium) in sulfobutylether cyclodextrin reaction mixtures achieved with the combined use of a strong anion exchange resin having dialkyl 2-hydroxyethyl ammonium hydroxide functionality and a cation exchange resin.
Type:
Grant
Filed:
June 10, 2021
Date of Patent:
May 16, 2023
Assignee:
CYCLOLAB CYCLODEXTRIN RESEARCH AND DEVELOPMENT LABORATORY LTD.
Inventors:
Tamas Sohajda, Gabriella Hirschbergne Szejtli, István Puskás
Abstract: Provided is a low-molecular-weight holothurian glycosarninoglycan, with the constituent units thereof being a glucuronic acid group, an N-acetaminogalactose group and a fucose group, and a sulfate ester group or acetyl ester group thereof. Glucuronic acid and N-acetaminogalactose are interconnected via ?(1-3) and ?(1-4) glucosidic bonds to form a backbone of a disaccharide repeating structural unit, and a fucose group is connected to the backbone as a side chain. On a molar ratio basis, the ratio of the glucuronic acid group:the N-acetaminogalactose group:the fucose group is 1:(0.8-1.2):(0.6-1.2). In the structure of the low-molecular-weight holothurian glycosaminoglycan, 10-30% of glucuronic acid groups are modified, on the 2-position, with a sulfate ester group, and the rest are hydroxyl groups; and a proportion of 10-30% of fucose groups is modified, on the 2-position, with an acetyl ester group, and the rest are hydroxyl or sulfate ester groups.
Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.
Type:
Grant
Filed:
July 24, 2019
Date of Patent:
May 9, 2023
Assignee:
ARC Medical Inc.
Inventors:
Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
Abstract: The invention relates to compositions of nicotinoyl ribosides and nicotinamide riboside derivatives and their methods of use. In some embodiments, the invention relates to methods of making nicotinoyl ribosides. In some embodiments, the invention relates to pharmaceutical compositions and nutritional supplements containing a nicotinoyl riboside. In further embodiments, the invention relates to methods of using nicotinoyl ribosides and nicotinamide riboside derivatives that promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival.
Abstract: Disclosed herein is a pharmaceutical composition comprising an iron carbohydrate complex for use in a method for treatment or prevention of an iron deficiency of a fetus or an infant, wherein the iron carbohydrate complex is administered to the mother of the fetus or infant.
Type:
Grant
Filed:
February 18, 2021
Date of Patent:
April 25, 2023
Assignee:
PHARMACOSMOS HOLDING A/S
Inventors:
Lars Lykke Thomsen, Tobias S. Christensen, Hans Andreasen
Abstract: This disclosure provides mixtures of beta-cyclodextrin molecules substituted at one or more hydroxyl positions by hydroxypropyl groups, the mixture optionally including unsubstituted beta-cyclodextrin molecules, for use as a pharmaceutically active ingredient; methods of making such mixtures; methods of qualifying such mixtures for use in a pharmaceutical composition suitable for intrathecal or intracerebroventricular administration; pharmaceutical compositions suitable for intrathecal or intracerebroventricular administration comprising such mixtures; and methods of using the pharmaceutical compositions for treatment of Niemann-Pick disease Type C.
Type:
Grant
Filed:
September 16, 2022
Date of Patent:
April 25, 2023
Assignee:
Mandos LLC
Inventors:
Bernardus Nicolaas Machielse, Allan Darling
Abstract: Provided herein are methods of preparing macrolides by the coupling of an eastern and western half, followed by macrocyclization, to provide macrolides, including both known and novel macrolides. Intermediates in the synthesis of macrolides including the eastern and western halves are also provided. Pharmaceutical compositions and methods of treating infectious diseases and inflammatory conditions using the inventive macrolides are also provided. A general diastereoselective aldol methodology used in the synthesis of the western half is further provided.
Type:
Grant
Filed:
December 4, 2020
Date of Patent:
April 25, 2023
Assignee:
President and Fellows of Harvard College
Inventors:
Andrew G. Myers, Ian Bass Seiple, Ziyang Zhang
Abstract: Certain embodiments of the invention provide a method for improving maternal and/or offspring health, comprising administering an effective amount of a nicotinamide adenine dinucleotide (NAD) precursor to a female mammal (e.g., pregnant or lactating female mammal).
Type:
Grant
Filed:
November 29, 2017
Date of Patent:
April 25, 2023
Assignee:
UNIVERSITY OF IOWA RESEARCH FOUNDATION
Inventors:
Charles M. Brenner, Po Hien Ear, Ankita Chadda, Marie E. Migaud, Hanna Stevens
Abstract: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
Type:
Grant
Filed:
December 14, 2020
Date of Patent:
April 25, 2023
Assignee:
Vertex Pharmaceuticals Incorporated
Inventors:
Yeeman K. Ramtohul, Sanjoy Kumar Das, Caroline Cadilhac, Thumkunta Jagadeeswar Reddy, Louis Vaillancourt, Michel Gallant, Bingcan Liu, Evelyne Dietrich, Frederic Vallee, Julien Martel, Carl Poisson
Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.
Type:
Grant
Filed:
July 24, 2019
Date of Patent:
April 18, 2023
Assignee:
ARC Medical Ine.
Inventors:
Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
Abstract: The present invention is directed to a process for purifying natamycin, to an all-trans polyene amphoteric macrolide, to a composition comprising said polyene amphoteric macrolide and to a process for preparing said polyene amphoteric macrolide.
Type:
Grant
Filed:
August 15, 2019
Date of Patent:
April 11, 2023
Assignee:
DSM IP ASSETS B.V.
Inventors:
Alexander Lucia Leonardus Duchateau, Peter Philip Lankhorst, Willebrordus Bernardus Van Scheppingen
Abstract: The present invention belongs to the field of biomedicine, specifically relates to the field of targeting medicine. More specifically, the present invention relates to a liver-targeting compound having thyroid hormone receptor agonist characteristics and a pharmaceutical composition thereof. The compound is a compound represented by formula (1). The compound can be used for treating and/or preventing diseases caused by thyroid hormone dysregulation, and can also effectively reduce lipids in plasma and liver cells.
Abstract: Reagents, methods, and kits for assaying enzymes associated with lysosomal storage diseases MPS-I, MPS-II, MPS-IIIA, MPS-IIIB, MPS-IVA, MPS-VI, and MPS VII.
Type:
Grant
Filed:
December 18, 2018
Date of Patent:
April 4, 2023
Assignee:
University of Washington through its Center for Commercialization
Inventors:
Michael H. Gelb, Arun Babu Kumar, Frances Hocutt, Zdenek Spacil, Mariana Natali Barcenas Rodriguez, Frantisek Turecek, C. Ronald Scott
Abstract: The present invention relates to the medical use of polysulfated polysaccharides and compositions thereof for the treatment of disease or disorders associated with bone marrow pathologies in the musculoskeletal system of a mammal. In particular, the invention relates to use of polysulfated polysaccharides, such as pentosan polysulfate, in treatment of bone marrow edema lesions or spinal Modic Endplate Changes as assessed by magnetic resonance imaging (MRI).
Abstract: The present disclosure generally describes methods of preparing 1?-cyano nucleosides, such as a compound of Formula (I). For example, the compound of Formula (I) can be prepared from a compound of Formula (II-a) in a flow reactor.
Type:
Grant
Filed:
March 11, 2021
Date of Patent:
March 28, 2023
Assignee:
Gilead Sciences, Inc.
Inventors:
Pavel R. Badalov, Stacy Bremner, Matthew R. Chin, Detian Gao, Nolan Griggs, Lars V. Heumann, Chiajen Lai, Robert R. Milburn, Sankar Mohan, Sean T. Neville, Bing Shi, Andrew C. Stevens, Nicholas A. J. Uhlig, Tiago Vieira, Todd A. Wenderski
Abstract: The subject of this invention are native forms of fucoidan polysaccharide, desulfated fucoidan and derivatives obtained by processing to the level of fucose-oligosaccarides containing preferentially, but not exclusively less than 20 monosaccaride fucose units alpha-linked by a glycosidic bond, with an average molecular weight of preferentially less than 3 kDa. The poly- and oligosaccarides that are described according to the invention are natural and safe, and are used as a dietary supplement for the use in prevention and treatment of pathologies associated with Noroviruses or Rotaviruses, Salmonella sp. or Pseudomonas aeruginosa or Campylobacter jejuni and other enteroviruses and enteric pathogens that cause bacterial gastroenteritis, as well as in the food production process. The invention also relates to a method for the desulfation and fragmentation of fucoidans to generate desulfated poly- or oligo-fucoses.
Type:
Grant
Filed:
October 5, 2018
Date of Patent:
March 21, 2023
Inventors:
Bojan Pavlovic, Franz-Georg Hanisch, Cem Aydogan
Abstract: Disclosed are chiral phosphoramidite auxiliary compositions for diastereoselective synthesis of stereochemically enriched oligonucleotides, and nucleoside phosphoramidite compounds comprising the same. Exemplary structures of the chiral phosphoramidite auxiliary compositions include Formulas (IA) and (IB).
Type:
Grant
Filed:
July 2, 2018
Date of Patent:
March 7, 2023
Assignee:
SIRIUS THERAPEUTICS, INC.
Inventors:
Sukumar Sakamuri, Curt W. Bradshaw, Dingguo Liu, Laxman Eltepu